English
简体中文
Total: £ 56.28
Published Date: 2026-02-12 | Pages: 116 | Tables: 112 | Medical Care
The global Toxoplasma Gondii Recombinant Antigen market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Toxoplasma Gondii Recombinant Antigen is a protein produced by genetic engineering technology that mimics the natural antigen of Toxoplasma gondii. Toxoplasma gondii is a parasite that causes toxoplasmosis in humans and animals. Recombinant antigens are used in in vitro diagnostic reagents to detect immune responses caused by Toxoplasma infection, such as the presence of antibodies. By using recombinant antigens, the specificity and sensitivity of diagnosis can be improved and cross-reactions and non-specific reactions can be reduced.
The North American market for Toxoplasma Gondii Recombinant Antigen is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Toxoplasma Gondii Recombinant Antigen is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Toxoplasma Gondii Recombinant Antigen in In Vitro Diagnostics is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Toxoplasma Gondii Recombinant Antigen include Rekom Biotech, Roche, Thermal Fisher, Bio-Rad, Abcam, Meridian Bioscience, Fapon Biotech, ViroGen Corporation, Medix Biochemica, Creative Diagnostics, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Toxoplasma Gondii Recombinant Antigen market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Toxoplasma Gondii Recombinant Antigen. The Toxoplasma Gondii Recombinant Antigen market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Toxoplasma Gondii Recombinant Antigen market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Toxoplasma Gondii Recombinant Antigen manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Rekom Biotech
Roche
Thermal Fisher
Bio-Rad
Abcam
Meridian Bioscience
Fapon Biotech
ViroGen Corporation
Medix Biochemica
Creative Diagnostics
Prospec
Cusabio
Abbexa
Segment by Type
Full-Length Antigen
Truncated Antigen
Segment by Application
In Vitro Diagnostics
Vaccine Development
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Toxoplasma Gondii Recombinant Antigen companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Toxoplasma Gondii Recombinant Antigen Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Full-Length Antigen
1.2.3 Truncated Antigen
1.3 Market by Application
1.3.1 Global Toxoplasma Gondii Recombinant Antigen Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 In Vitro Diagnostics
1.3.3 Vaccine Development
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Toxoplasma Gondii Recombinant Antigen Market Perspective (2021–2032)
2.2 Global Toxoplasma Gondii Recombinant Antigen Growth Trends by Region
2.2.1 Global Toxoplasma Gondii Recombinant Antigen Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Toxoplasma Gondii Recombinant Antigen Historic Market Size by Region (2021–2026)
2.2.3 Toxoplasma Gondii Recombinant Antigen Forecasted Market Size by Region (2027–2032)
2.3 Toxoplasma Gondii Recombinant Antigen Market Dynamics
2.3.1 Toxoplasma Gondii Recombinant Antigen Industry Trends
2.3.2 Toxoplasma Gondii Recombinant Antigen Market Drivers
2.3.3 Toxoplasma Gondii Recombinant Antigen Market Challenges
2.3.4 Toxoplasma Gondii Recombinant Antigen Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Toxoplasma Gondii Recombinant Antigen Players by Revenue
3.1.1 Global Top Toxoplasma Gondii Recombinant Antigen Players by Revenue (2021–2026)
3.1.2 Global Toxoplasma Gondii Recombinant Antigen Revenue Market Share by Players (2021–2026)
3.2 Global Top Toxoplasma Gondii Recombinant Antigen Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Toxoplasma Gondii Recombinant Antigen Revenue
3.4 Global Toxoplasma Gondii Recombinant Antigen Market Concentration Ratio
3.4.1 Global Toxoplasma Gondii Recombinant Antigen Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Toxoplasma Gondii Recombinant Antigen Revenue in 2025
3.5 Global Key Players of Toxoplasma Gondii Recombinant Antigen Head Offices and Areas Served
3.6 Global Key Players of Toxoplasma Gondii Recombinant Antigen, Products and Applications
3.7 Global Key Players of Toxoplasma Gondii Recombinant Antigen, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Toxoplasma Gondii Recombinant Antigen Breakdown Data by Type
4.1 Global Toxoplasma Gondii Recombinant Antigen Historic Market Size by Type (2021–2026)
4.2 Global Toxoplasma Gondii Recombinant Antigen Forecasted Market Size by Type (2027–2032)
5 Toxoplasma Gondii Recombinant Antigen Breakdown Data by Application
5.1 Global Toxoplasma Gondii Recombinant Antigen Historic Market Size by Application (2021–2026)
5.2 Global Toxoplasma Gondii Recombinant Antigen Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Toxoplasma Gondii Recombinant Antigen Market Size (2021–2032)
6.2 North America Toxoplasma Gondii Recombinant Antigen Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Toxoplasma Gondii Recombinant Antigen Market Size by Country (2021–2026)
6.4 North America Toxoplasma Gondii Recombinant Antigen Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Toxoplasma Gondii Recombinant Antigen Market Size (2021–2032)
7.2 Europe Toxoplasma Gondii Recombinant Antigen Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Toxoplasma Gondii Recombinant Antigen Market Size by Country (2021–2026)
7.4 Europe Toxoplasma Gondii Recombinant Antigen Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Toxoplasma Gondii Recombinant Antigen Market Size (2021–2032)
8.2 Asia-Pacific Toxoplasma Gondii Recombinant Antigen Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Toxoplasma Gondii Recombinant Antigen Market Size by Region (2021–2026)
8.4 Asia-Pacific Toxoplasma Gondii Recombinant Antigen Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Toxoplasma Gondii Recombinant Antigen Market Size (2021–2032)
9.2 Latin America Toxoplasma Gondii Recombinant Antigen Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Toxoplasma Gondii Recombinant Antigen Market Size by Country (2021–2026)
9.4 Latin America Toxoplasma Gondii Recombinant Antigen Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Toxoplasma Gondii Recombinant Antigen Market Size (2021–2032)
10.2 Middle East & Africa Toxoplasma Gondii Recombinant Antigen Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Toxoplasma Gondii Recombinant Antigen Market Size by Country (2021–2026)
10.4 Middle East & Africa Toxoplasma Gondii Recombinant Antigen Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Rekom Biotech
11.1.1 Rekom Biotech Company Details
11.1.2 Rekom Biotech Business Overview
11.1.3 Rekom Biotech Toxoplasma Gondii Recombinant Antigen Introduction
11.1.4 Rekom Biotech Revenue in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
11.1.5 Rekom Biotech Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Toxoplasma Gondii Recombinant Antigen Introduction
11.2.4 Roche Revenue in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
11.2.5 Roche Recent Development
11.3 Thermal Fisher
11.3.1 Thermal Fisher Company Details
11.3.2 Thermal Fisher Business Overview
11.3.3 Thermal Fisher Toxoplasma Gondii Recombinant Antigen Introduction
11.3.4 Thermal Fisher Revenue in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
11.3.5 Thermal Fisher Recent Development
11.4 Bio-Rad
11.4.1 Bio-Rad Company Details
11.4.2 Bio-Rad Business Overview
11.4.3 Bio-Rad Toxoplasma Gondii Recombinant Antigen Introduction
11.4.4 Bio-Rad Revenue in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
11.4.5 Bio-Rad Recent Development
11.5 Abcam
11.5.1 Abcam Company Details
11.5.2 Abcam Business Overview
11.5.3 Abcam Toxoplasma Gondii Recombinant Antigen Introduction
11.5.4 Abcam Revenue in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
11.5.5 Abcam Recent Development
11.6 Meridian Bioscience
11.6.1 Meridian Bioscience Company Details
11.6.2 Meridian Bioscience Business Overview
11.6.3 Meridian Bioscience Toxoplasma Gondii Recombinant Antigen Introduction
11.6.4 Meridian Bioscience Revenue in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
11.6.5 Meridian Bioscience Recent Development
11.7 Fapon Biotech
11.7.1 Fapon Biotech Company Details
11.7.2 Fapon Biotech Business Overview
11.7.3 Fapon Biotech Toxoplasma Gondii Recombinant Antigen Introduction
11.7.4 Fapon Biotech Revenue in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
11.7.5 Fapon Biotech Recent Development
11.8 ViroGen Corporation
11.8.1 ViroGen Corporation Company Details
11.8.2 ViroGen Corporation Business Overview
11.8.3 ViroGen Corporation Toxoplasma Gondii Recombinant Antigen Introduction
11.8.4 ViroGen Corporation Revenue in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
11.8.5 ViroGen Corporation Recent Development
11.9 Medix Biochemica
11.9.1 Medix Biochemica Company Details
11.9.2 Medix Biochemica Business Overview
11.9.3 Medix Biochemica Toxoplasma Gondii Recombinant Antigen Introduction
11.9.4 Medix Biochemica Revenue in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
11.9.5 Medix Biochemica Recent Development
11.10 Creative Diagnostics
11.10.1 Creative Diagnostics Company Details
11.10.2 Creative Diagnostics Business Overview
11.10.3 Creative Diagnostics Toxoplasma Gondii Recombinant Antigen Introduction
11.10.4 Creative Diagnostics Revenue in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
11.10.5 Creative Diagnostics Recent Development
11.11 Prospec
11.11.1 Prospec Company Details
11.11.2 Prospec Business Overview
11.11.3 Prospec Toxoplasma Gondii Recombinant Antigen Introduction
11.11.4 Prospec Revenue in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
11.11.5 Prospec Recent Development
11.12 Cusabio
11.12.1 Cusabio Company Details
11.12.2 Cusabio Business Overview
11.12.3 Cusabio Toxoplasma Gondii Recombinant Antigen Introduction
11.12.4 Cusabio Revenue in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
11.12.5 Cusabio Recent Development
11.13 Abbexa
11.13.1 Abbexa Company Details
11.13.2 Abbexa Business Overview
11.13.3 Abbexa Toxoplasma Gondii Recombinant Antigen Introduction
11.13.4 Abbexa Revenue in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
11.13.5 Abbexa Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Toxoplasma Gondii Recombinant Antigen Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Full-Length Antigen
Table 3. Key Players of Truncated Antigen
Table 4. Global Toxoplasma Gondii Recombinant Antigen Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 5. Global Toxoplasma Gondii Recombinant Antigen Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 6. Global Toxoplasma Gondii Recombinant Antigen Market Size by Region (US$ Million), 2021–2026
Table 7. Global Toxoplasma Gondii Recombinant Antigen Market Share by Region (2021–2026)
Table 8. Global Toxoplasma Gondii Recombinant Antigen Forecasted Market Size by Region (US$ Million), 2027–2032
Table 9. Global Toxoplasma Gondii Recombinant Antigen Market Share by Region (2027–2032)
Table 10. Toxoplasma Gondii Recombinant Antigen Market Trends
Table 11. Toxoplasma Gondii Recombinant Antigen Market Drivers
Table 12. Toxoplasma Gondii Recombinant Antigen Market Challenges
Table 13. Toxoplasma Gondii Recombinant Antigen Market Restraints
Table 14. Global Toxoplasma Gondii Recombinant Antigen Revenue by Players (US$ Million), 2021–2026
Table 15. Global Toxoplasma Gondii Recombinant Antigen Market Share by Players (2021–2026)
Table 16. Global Top Toxoplasma Gondii Recombinant Antigen Players by Tier (Tier 1, Tier 2, and Tier 3), based on Toxoplasma Gondii Recombinant Antigen Revenue, 2025
Table 17. Ranking of Global Top Toxoplasma Gondii Recombinant Antigen Companies by Revenue (US$ Million) in 2025
Table 18. Global 5 Largest Players Market Share by Toxoplasma Gondii Recombinant Antigen Revenue (CR5 and HHI), 2021–2026
Table 19. Global Key Players of Toxoplasma Gondii Recombinant Antigen, Headquarters and Area Served
Table 20. Global Key Players of Toxoplasma Gondii Recombinant Antigen, Products and Applications
Table 21. Global Key Players of Toxoplasma Gondii Recombinant Antigen, Date of General Availability (GA)
Table 22. Mergers and Acquisitions, Expansion Plans
Table 23. Global Toxoplasma Gondii Recombinant Antigen Market Size by Type (US$ Million), 2021–2026
Table 24. Global Toxoplasma Gondii Recombinant Antigen Revenue Market Share by Type (2021–2026)
Table 25. Global Toxoplasma Gondii Recombinant Antigen Forecasted Market Size by Type (US$ Million), 2027–2032
Table 26. Global Toxoplasma Gondii Recombinant Antigen Revenue Market Share by Type (2027–2032)
Table 27. Global Toxoplasma Gondii Recombinant Antigen Market Size by Application (US$ Million), 2021–2026
Table 28. Global Toxoplasma Gondii Recombinant Antigen Revenue Market Share by Application (2021–2026)
Table 29. Global Toxoplasma Gondii Recombinant Antigen Forecasted Market Size by Application (US$ Million), 2027–2032
Table 30. Global Toxoplasma Gondii Recombinant Antigen Revenue Market Share by Application (2027–2032)
Table 31. North America Toxoplasma Gondii Recombinant Antigen Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 32. North America Toxoplasma Gondii Recombinant Antigen Market Size by Country (US$ Million), 2021–2026
Table 33. North America Toxoplasma Gondii Recombinant Antigen Market Size by Country (US$ Million), 2027–2032
Table 34. Europe Toxoplasma Gondii Recombinant Antigen Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 35. Europe Toxoplasma Gondii Recombinant Antigen Market Size by Country (US$ Million), 2021–2026
Table 36. Europe Toxoplasma Gondii Recombinant Antigen Market Size by Country (US$ Million), 2027–2032
Table 37. Asia-Pacific Toxoplasma Gondii Recombinant Antigen Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 38. Asia-Pacific Toxoplasma Gondii Recombinant Antigen Market Size by Region (US$ Million), 2021–2026
Table 39. Asia-Pacific Toxoplasma Gondii Recombinant Antigen Market Size by Region (US$ Million), 2027–2032
Table 40. Latin America Toxoplasma Gondii Recombinant Antigen Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 41. Latin America Toxoplasma Gondii Recombinant Antigen Market Size by Country (US$ Million), 2021–2026
Table 42. Latin America Toxoplasma Gondii Recombinant Antigen Market Size by Country (US$ Million), 2027–2032
Table 43. Middle East & Africa Toxoplasma Gondii Recombinant Antigen Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 44. Middle East & Africa Toxoplasma Gondii Recombinant Antigen Market Size by Country (US$ Million), 2021–2026
Table 45. Middle East & Africa Toxoplasma Gondii Recombinant Antigen Market Size by Country (US$ Million), 2027–2032
Table 46. Rekom Biotech Company Details
Table 47. Rekom Biotech Business Overview
Table 48. Rekom Biotech Toxoplasma Gondii Recombinant Antigen Product
Table 49. Rekom Biotech Revenue in Toxoplasma Gondii Recombinant Antigen Business (US$ Million), 2021–2026
Table 50. Rekom Biotech Recent Development
Table 51. Roche Company Details
Table 52. Roche Business Overview
Table 53. Roche Toxoplasma Gondii Recombinant Antigen Product
Table 54. Roche Revenue in Toxoplasma Gondii Recombinant Antigen Business (US$ Million), 2021–2026
Table 55. Roche Recent Development
Table 56. Thermal Fisher Company Details
Table 57. Thermal Fisher Business Overview
Table 58. Thermal Fisher Toxoplasma Gondii Recombinant Antigen Product
Table 59. Thermal Fisher Revenue in Toxoplasma Gondii Recombinant Antigen Business (US$ Million), 2021–2026
Table 60. Thermal Fisher Recent Development
Table 61. Bio-Rad Company Details
Table 62. Bio-Rad Business Overview
Table 63. Bio-Rad Toxoplasma Gondii Recombinant Antigen Product
Table 64. Bio-Rad Revenue in Toxoplasma Gondii Recombinant Antigen Business (US$ Million), 2021–2026
Table 65. Bio-Rad Recent Development
Table 66. Abcam Company Details
Table 67. Abcam Business Overview
Table 68. Abcam Toxoplasma Gondii Recombinant Antigen Product
Table 69. Abcam Revenue in Toxoplasma Gondii Recombinant Antigen Business (US$ Million), 2021–2026
Table 70. Abcam Recent Development
Table 71. Meridian Bioscience Company Details
Table 72. Meridian Bioscience Business Overview
Table 73. Meridian Bioscience Toxoplasma Gondii Recombinant Antigen Product
Table 74. Meridian Bioscience Revenue in Toxoplasma Gondii Recombinant Antigen Business (US$ Million), 2021–2026
Table 75. Meridian Bioscience Recent Development
Table 76. Fapon Biotech Company Details
Table 77. Fapon Biotech Business Overview
Table 78. Fapon Biotech Toxoplasma Gondii Recombinant Antigen Product
Table 79. Fapon Biotech Revenue in Toxoplasma Gondii Recombinant Antigen Business (US$ Million), 2021–2026
Table 80. Fapon Biotech Recent Development
Table 81. ViroGen Corporation Company Details
Table 82. ViroGen Corporation Business Overview
Table 83. ViroGen Corporation Toxoplasma Gondii Recombinant Antigen Product
Table 84. ViroGen Corporation Revenue in Toxoplasma Gondii Recombinant Antigen Business (US$ Million), 2021–2026
Table 85. ViroGen Corporation Recent Development
Table 86. Medix Biochemica Company Details
Table 87. Medix Biochemica Business Overview
Table 88. Medix Biochemica Toxoplasma Gondii Recombinant Antigen Product
Table 89. Medix Biochemica Revenue in Toxoplasma Gondii Recombinant Antigen Business (US$ Million), 2021–2026
Table 90. Medix Biochemica Recent Development
Table 91. Creative Diagnostics Company Details
Table 92. Creative Diagnostics Business Overview
Table 93. Creative Diagnostics Toxoplasma Gondii Recombinant Antigen Product
Table 94. Creative Diagnostics Revenue in Toxoplasma Gondii Recombinant Antigen Business (US$ Million), 2021–2026
Table 95. Creative Diagnostics Recent Development
Table 96. Prospec Company Details
Table 97. Prospec Business Overview
Table 98. Prospec Toxoplasma Gondii Recombinant Antigen Product
Table 99. Prospec Revenue in Toxoplasma Gondii Recombinant Antigen Business (US$ Million), 2021–2026
Table 100. Prospec Recent Development
Table 101. Cusabio Company Details
Table 102. Cusabio Business Overview
Table 103. Cusabio Toxoplasma Gondii Recombinant Antigen Product
Table 104. Cusabio Revenue in Toxoplasma Gondii Recombinant Antigen Business (US$ Million), 2021–2026
Table 105. Cusabio Recent Development
Table 106. Abbexa Company Details
Table 107. Abbexa Business Overview
Table 108. Abbexa Toxoplasma Gondii Recombinant Antigen Product
Table 109. Abbexa Revenue in Toxoplasma Gondii Recombinant Antigen Business (US$ Million), 2021–2026
Table 110. Abbexa Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
Table 114. Authors List of This Report
List of Figures
Figure 1. Toxoplasma Gondii Recombinant Antigen Picture
Figure 2. Global Toxoplasma Gondii Recombinant Antigen Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Toxoplasma Gondii Recombinant Antigen Market Share by Type: 2025 vs 2032
Figure 4. Full-Length Antigen Features
Figure 5. Truncated Antigen Features
Figure 6. Global Toxoplasma Gondii Recombinant Antigen Market Size by Application (US$ Million), 2021–2032
Figure 7. Global Toxoplasma Gondii Recombinant Antigen Market Share by Application: 2025 vs 2032
Figure 8. In Vitro Diagnostics Case Studies
Figure 9. Vaccine Development Case Studies
Figure 10. Others Case Studies
Figure 11. Toxoplasma Gondii Recombinant Antigen Report Years Considered
Figure 12. Global Toxoplasma Gondii Recombinant Antigen Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 13. Global Toxoplasma Gondii Recombinant Antigen Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Toxoplasma Gondii Recombinant Antigen Market Share by Region: 2025 vs 2032
Figure 15. Global Toxoplasma Gondii Recombinant Antigen Market Share by Players in 2025
Figure 16. Global Toxoplasma Gondii Recombinant Antigen Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 17. The Top 10 and 5 Players Market Share by Toxoplasma Gondii Recombinant Antigen Revenue in 2025
Figure 18. North America Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 19. North America Toxoplasma Gondii Recombinant Antigen Market Share by Country (2021–2032)
Figure 20. United States Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 21. Canada Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. Europe Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Europe Toxoplasma Gondii Recombinant Antigen Market Share by Country (2021–2032)
Figure 24. Germany Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. France Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. U.K. Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. Italy Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. Russia Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Ireland Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Asia-Pacific Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Asia-Pacific Toxoplasma Gondii Recombinant Antigen Market Share by Region (2021–2032)
Figure 32. China Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Japan Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. South Korea Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Southeast Asia Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. India Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Australia & New Zealand Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Latin America Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Latin America Toxoplasma Gondii Recombinant Antigen Market Share by Country (2021–2032)
Figure 40. Mexico Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Brazil Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Middle East & Africa Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Middle East & Africa Toxoplasma Gondii Recombinant Antigen Market Share by Country (2021–2032)
Figure 44. Israel Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Saudi Arabia Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. UAE Toxoplasma Gondii Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Rekom Biotech Revenue Growth Rate in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
Figure 48. Roche Revenue Growth Rate in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
Figure 49. Thermal Fisher Revenue Growth Rate in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
Figure 50. Bio-Rad Revenue Growth Rate in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
Figure 51. Abcam Revenue Growth Rate in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
Figure 52. Meridian Bioscience Revenue Growth Rate in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
Figure 53. Fapon Biotech Revenue Growth Rate in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
Figure 54. ViroGen Corporation Revenue Growth Rate in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
Figure 55. Medix Biochemica Revenue Growth Rate in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
Figure 56. Creative Diagnostics Revenue Growth Rate in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
Figure 57. Prospec Revenue Growth Rate in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
Figure 58. Cusabio Revenue Growth Rate in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
Figure 59. Abbexa Revenue Growth Rate in Toxoplasma Gondii Recombinant Antigen Business (2021–2026)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
